#serotonin2a — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #serotonin2a, aggregated by home.social.
-
DATE: September 10, 2026 at 08:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Psilocybin prevents chemotherapy-induced nerve damage in new preclinical study
Recent research suggests that giving mice a compound found in magic mushrooms before chemotherapy can prevent the debilitating nerve damage that often accompanies cancer treatment. The findings indicate that psilocybin protects nerve fibers by keeping their cellular powerhouses moving and functioning properly. The study was published in Science.
Chemotherapy-induced peripheral neuropathy is a condition where cancer drugs damage the long sensory nerves that extend from the spinal cord to the hands and feet. This damage leads to pain, numbness, and an extreme sensitivity to cold. Because the condition can be severe and long-lasting, doctors often have to reduce a patient’s chemotherapy dose or stop the treatment entirely.
“Almost everyone who gets any of the most common cancer chemotherapies for all the most common cancers will develop peripheral neuropathy that can be experienced as mild numbness, tingling, to pins and needles or to most severe as continuous burning sensations,” said study co-author Patrick M. Dougherty, a professor of pain medicine research at The University of Texas MD Anderson Cancer Center.
“This is in spite of the fact that none of these cancer drugs are given at the maximum dose to kill cancer cells, but at lesser doses to avoid neurotoxicity,” he told PsyPost. “While many patients will improve over time, others suffer this negative impact for years.”
Medical scientists have worked to understand exactly how these drugs harm the nerves. For example, a 2014 review established that chemotherapy agents tend to damage mitochondria, the small structures inside cells that generate energy. These energy factories are especially important for sensory nerves, which require a constant supply of power along their extensive, thread-like extensions, called axons.
Subsequent work, such as a 2024 study, demonstrated that keeping mitochondria moving along these nerve fibers helps shield them from the physical degeneration caused by chemotherapy. In a parallel area of study, a 2018 study provided evidence that psychedelic compounds can stimulate specific growth pathways to rebuild and protect nerve connections.
The authors of the new study connected these pieces of evidence. Psilocybin, the active ingredient in certain mushroom species, activates a specific receptor on the surface of cells known as the serotonin 2A receptor. Because this receptor is involved in both nerve adaptability and mitochondrial regulation, the scientists hypothesized that administering psilocybin before chemotherapy might trigger a protective rescue mechanism, preventing the nerve damage before it begins.
“Interventions for pre-established neuropathy have not worked out, so the goal here was to find a way to protect the nervous system to keep neuropathy from ever developing,” Dougherty explained.
“There is an urgent need for treatments that prevent nerve injury without interfering with lifesaving chemotherapy,” added study co-leader Moran Amit, an assistant professor of head and neck surgery at The University of Texas MD Anderson Cancer Center. “These findings offer important insights into how psilocybin may protect nerves before damage occurs, rather than treating symptoms after they become persistent.”
The research, co-led by Dougherty and Amit, utilized a combination of mouse behavioral models and human tissue analysis. To test their hypothesis, the scientists gave mice two doses of psilocybin before administering common chemotherapy drugs, such as cisplatin and paclitaxel. They then subjected the mice to up to six cycles of chemotherapy, mimicking a clinical treatment schedule.
To measure nerve damage, the researchers tested the animals’ responses to physical pressure and cold temperatures over the course of eight months. The team also used mice with oral tumors to check if psilocybin interfered with the chemotherapy’s ability to shrink the cancer.
In addition to the animal models, the researchers examined human sensory neurons grown in the lab. They also looked at fresh peripheral nerve tissue taken from 29 human surgical patients. Using advanced live-cell imaging, they watched how mitochondria moved inside these human nerve fibers when exposed to chemotherapy with and without psilocybin.
The scientists found that just two preventive doses of psilocybin kept the mice from developing the physical hypersensitivity and cold sensitivity typically caused by the chemotherapy drugs. The mice maintained normal baseline sensitivity scores, and this protective effect lasted across all six cycles of treatment and throughout the eight-month follow-up period.
Notably, psilocybin did not reduce the cancer-killing effectiveness of the chemotherapy. The tumor-bearing mice that received psilocybin showed the same reduction in tumor size as those that only received chemotherapy. Systemic immune markers also remained unchanged, suggesting the treatment targets the nerves without altering the body’s general response to cancer.
The team discovered that psilocybin operates through two distinct pathways to achieve this protection. In the brain, it helped normalize electrical activity that is typically disrupted by chronic pain. In the peripheral body, it directly protected the structure and function of the sensory nerve endings in the skin.
When looking closely at the nerve cells, the researchers noticed that chemotherapy ordinarily causes mitochondria to stall, halting their journey down the long nerve axons. This starvation of energy at the distant nerve endings leads to their structural decay. Psilocybin prevented this traffic jam.
By activating the serotonin 2A receptor, psilocybin engaged a specific signaling chain that controls the molecular motors responsible for transporting mitochondria. By keeping the mitochondria moving, psilocybin ensured the nerve endings received the energy they needed to survive the toxic stress of the chemotherapy.
“Psilocybin does more than reduce pain signals by protecting the nerves themselves through energy delivery,” Dougherty noted. “This neuroprotective effect could help patients withstand the stress of chemotherapy, maintaining sensation, mobility and quality of life during treatment and long into survivorship.”
The researchers also found that the hallucinogenic effects of psilocybin were not strictly necessary for this nerve protection. When they treated mice with a nonhallucinogenic compound that targets the exact same serotonin 2A receptors, the animals received an equivalent level of protection against the nerve damage.
The findings are in line with research covered by PsyPost in 2026, which found that a single dose of psilocybin reduced neuropathic pain sensitivity in mice. It is worth noting that the older study evaluated treating established pain via central brain remodeling, whereas the new study evaluated preventing the pain prophylactically by preserving peripheral nerve function. Another study covered by PsyPost later in 2026 similarly demonstrated psilocybin’s ability to calm pain networks in rodents, again focusing on existing central pain rather than preventing peripheral damage.
As with all research, there are some caveats to consider. The study relies heavily on mouse models and isolated human tissues. Laboratory tests on human nerve cells provided promising outcomes, but clinical trials involving human patients are needed to see if the preventive treatment works safely and effectively in a real-world medical setting.
“The study offers an interesting mechanistic and preclinical rationale for investigating psilocybin in chemotherapy-induced peripheral neuropathy, particularly through its potential effects on mitochondrial trafficking and neuronal resilience,” said Andres Ort, a physician and member of the Neurophenomenology of Consciousness Lab at the University of Zurich who was not involved in the research.
“However, the findings should not be interpreted as evidence that psilocybin prevents or treats chemotherapy-induced neuropathy in patients,” Ort told PsyPost. “The translational gap between experimental models and clinical oncology remains substantial, and questions around dosing, timing, safety, drug interactions, psychiatric screening, blinding, and meaningful patient-centered outcomes will need careful evaluation.”
“The prospect of self-medication would be best avoided,” Dougherty cautioned. “If the work is validated, access to psilocybin would come to be available through your oncologist.”
It is also important to note that the timing of the treatment appears strict. The study indicates that psilocybin only works as a preventive measure in this context. When the researchers tried administering chemotherapy first and waiting for the nerve damage to set in, the psilocybin did not reverse the injury. Patients would likely need to receive the compound before every cycle of chemotherapy to maintain the protective effect.
Despite these constraints, the researchers are optimistic about the drug’s clinical potential. “The results of this study are very promising and have opened a new angle for potential therapeutic intervention in chemotherapy-induced peripheral neuropathy,” Dougherty said.
The team is already moving forward with an upcoming Phase 2 clinical trial, called NeuroGuard, to evaluate psilocybin during chemotherapy in patients with multiple cancer types. “A clinical trial will be opening soon for patients receiving cisplatin, but other chemotherapies will now also need to be tested to determine whether psilocybin may protect from their neurotoxicities,” Dougherty added.
“The most important next step is a well-designed, adequately powered clinical trial assessing not only neuropathy symptoms, but also function, quality of life, cancer-treatment adherence, and safety in the relevant oncology population,” Ort noted.
“If this work holds up, it may be a therapy integrated to all cancers,” Dougherty explained. “This would impact the approximately 2,000,000 new cancer cases expected in 2026, based on 2025 numbers in just the US.”
This work is part of UT MD Anderson’s Cancer Neuroscience Program, which examines the interactions between cancer and the nervous system. “At UT MD Anderson, we are actively exploring the multiple facets of psychedelics to pursue interventions that improve the lives of our patients,” Amit concluded.
The study, “Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation,” was authored by Mario Heles, Lilach Pasvolsky, Hinduja Sathishkumar, Shorook Naara, Yen Vu, Caitlyn L. Stewart, Tongxin Xie, Frederico O. Gleber-Netto, William McCarthy, Dan Yaniv, Shashank S. Kamal, Hajira Elahi, Pengyu Zhu, Megan L. Uhelski, Jordan Chatwin, Andrew Lara, Danielle L. Stolley, Michael R. Migden, Z-Hye Lee, Shiyanth Thevasagayampillai, Preethi H. Gunaratne, Kaoutar Ait-Ahmad, M. J. Kuykendall, Sebnem Ece Eksi, Lorenzo Cohen, Jeremy C. Borniger, Eyal Gottlieb, Gregory H. Jones, Patrick M. Dougherty, and Moran Amit.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #PsilocybinTherapy #ChemotherapyNeuropathy #MitochondrialTrafficking #NerveProtection #PeripheralNeuropathyPrevention #Serotonin2A #PsychedelicsInMedicine #CancerTreatmentSupport #NeuroGuardTrial #ScienceNews